Michael J. Koren on Muck Rack

Michael J. Koren

Jacksonville
As seen in: Apple Podcasts, Wiley, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, The New England Journal of Medicine, The Lancet, AHA/ASA Journals, Healio, Healio Cardiology, JACC (Journal of the American College of Cardiology) and
Cardiologist; CEO, Encore Research; President, Academy of Physicians in Clinical Research
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael J.

Contact Michael J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Analysing the Evolution of LDL-C Management: A Review of Emerging Data at the ACC

|
By Michael J. Koren, Neha J. Pagidipati
| RadcliffeCardiology.com Verified
Overview This IME peer-to-peer discussion took place at the American College of Cardiology (ACC) Congress and focused on emerging data in dyslipidaemia, with particular emphasis on PCSK9 inhibition. Centred on findings from the PURSUIT trial, the programme explored the evolving role of PCSK9 therapies and their potential impact on lipid management strategies.
Open in Who Shared Issue with article?

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial

|
By Michael J. Koren, Rick Vega, Nikhil Agrawal, Yuejia Xu
| JACC (Journal of the American College of Cardiology)
Introduction The clinical strategy of aggressively reducing low-density lipoprotein cholesterol (LDL-C) to prevent adverse cardiovascular (CV) events in high-risk patients has consistently and unambiguously shown that “lower is better.”1-5 Scores of high-quality clinical trials have led to the current consensus approach for treating hypercholesterolemia starting with statin therapy.1,6-9 Clinicians typically prescribe an effective statin, such as atorvastatin or rosuvastatin, titrated to the...
Open in Who Shared Issue with article?

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)

|
By Steven Nissen, Kathy E. Wolski, Gerald Watts, Michael J. Koren
| JAMA: Journal of the American Medical Association Verified
Key Points Question What is the safety and tolerability of zerlasiran and its effect on lipoprotein(a) serum concentrations? Findings The trial enrolled 32 healthy participants and 36 patients with cardiovascular disease and lipoprotein(a) concentrations 150 nmol/L or greater. No serious adverse event occurred. The median change from baseline in lipoprotein(a) concentration 365 days after single doses for placebo, 300 mg, and 600 mg were 14%, −30%, and −29%.
Open in Who Shared Issue with article?
See all 17 licensed articles (18 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified